NCT04537234View on ClinicalTrials.gov

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

PHASE3CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

February 9, 2021

Study Completion Date

February 9, 2021

Conditions
Influenza (Healthy Volunteers)
Interventions
BIOLOGICAL

High-Dose Quadrivalent Influenza Vaccine

"Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM"

BIOLOGICAL

Standard-Dose Quadrivalent Influenza Vaccine

"Pharmaceutical form: Suspension for injection in pre-filled syringe,~Route of administration: IM"

Trial Locations (4)

100

Investigational Site Number 1580001, Taipei

112

Investigational Site Number 1580002, Taipei

333

Investigational Site Number 1580003, Taoyuan District

40447

Investigational Site Number 1580004, Taichung

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT04537234 - Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older | Biotech Hunter | Biotech Hunter